HK1152048A1 - 難辨梭狀芽孢桿菌毒素的抗體及其用途 - Google Patents

難辨梭狀芽孢桿菌毒素的抗體及其用途

Info

Publication number
HK1152048A1
HK1152048A1 HK11105869.4A HK11105869A HK1152048A1 HK 1152048 A1 HK1152048 A1 HK 1152048A1 HK 11105869 A HK11105869 A HK 11105869A HK 1152048 A1 HK1152048 A1 HK 1152048A1
Authority
HK
Hong Kong
Prior art keywords
antibodies against
clostridium difficile
difficile toxins
against clostridium
toxins
Prior art date
Application number
HK11105869.4A
Other languages
English (en)
Inventor
Donna Ambrosino
Gregory J Babcock
Theresa Broering
Robert Graziano
Hector Javier Hernandez
Israel Lowy
Robert Mandell
Deborah Molrine
William D Thomas
Hui-Fen Zhang
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36928722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1152048(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Publication of HK1152048A1 publication Critical patent/HK1152048A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
HK11105869.4A 2004-02-06 2007-09-25 難辨梭狀芽孢桿菌毒素的抗體及其用途 HK1152048A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54235704P 2004-02-06 2004-02-06
US61385404P 2004-09-28 2004-09-28

Publications (1)

Publication Number Publication Date
HK1152048A1 true HK1152048A1 (zh) 2012-02-17

Family

ID=36928722

Family Applications (3)

Application Number Title Priority Date Filing Date
HK07110397.1A HK1102287A1 (en) 2004-02-06 2007-09-25 Antibodies against clostridium difficile toxins and uses thereof
HK11105869.4A HK1152048A1 (zh) 2004-02-06 2007-09-25 難辨梭狀芽孢桿菌毒素的抗體及其用途
HK15109420.4A HK1208873A1 (zh) 2004-02-06 2015-09-24 反艱難梭菌毒素抗體及其應用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK07110397.1A HK1102287A1 (en) 2004-02-06 2007-09-25 Antibodies against clostridium difficile toxins and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15109420.4A HK1208873A1 (zh) 2004-02-06 2015-09-24 反艱難梭菌毒素抗體及其應用

Country Status (26)

Country Link
US (8) US7625559B2 (zh)
EP (3) EP1766093B1 (zh)
JP (3) JP4588763B2 (zh)
KR (3) KR101332994B1 (zh)
CN (1) CN101014620B (zh)
AT (1) ATE512986T1 (zh)
AU (1) AU2005320349C1 (zh)
BR (1) BRPI0507433C1 (zh)
CA (1) CA2553946C (zh)
CY (3) CY1111860T1 (zh)
DK (3) DK1766093T3 (zh)
ES (3) ES2366626T3 (zh)
HK (3) HK1102287A1 (zh)
HR (1) HRP20110599T1 (zh)
HU (3) HUE024962T2 (zh)
LT (2) LT2857418T (zh)
LU (1) LUC00025I2 (zh)
MX (1) MXPA06008839A (zh)
NO (2) NO340300B1 (zh)
NZ (2) NZ548821A (zh)
PL (3) PL2857418T3 (zh)
PT (3) PT2270045E (zh)
RS (1) RS51908B (zh)
SI (3) SI2857418T1 (zh)
WO (1) WO2006121422A2 (zh)
ZA (1) ZA200606516B (zh)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CA2553946C (en) 2004-02-06 2019-02-26 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
CA2575768C (en) * 2004-06-28 2012-12-04 Japan Science And Technology Agency Method for screening toxin neutralizing peptide, stx2 inhibiting peptide and verotoxin neutralizing agent
AU2005321974B2 (en) * 2004-12-27 2011-11-17 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
WO2008014733A1 (de) * 2006-08-02 2008-02-07 Johannes Gutenberg-Universität Mainz Arzneimittel gegen lct-vergiftungen
CN107011431B (zh) 2007-01-30 2020-11-06 埃皮瓦克斯公司 调节性t细胞表位、组合物及其用途
AU2014201846B2 (en) * 2007-01-30 2016-07-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US20080188007A1 (en) * 2007-02-06 2008-08-07 Meridian Life Science, Inc. Fluorescent single chain antibody and its use in detection of analytes
CN101363867B (zh) * 2008-05-26 2012-12-19 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法
EP2293667A4 (en) * 2008-05-27 2012-07-18 Kyowa Hakko Kirin Co Ltd INTERLEUKIN 10 (IL-10R) RECEPTOR ANTIBODIES AND METHODS OF USE
DE102008029688B4 (de) * 2008-06-24 2016-06-23 Biodics Gmbh Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe
JP5740714B2 (ja) * 2009-02-20 2015-06-24 ヘルス プロテクション エージェンシー クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体
CA2768528C (en) * 2009-07-27 2017-05-23 Christoph Von Eichel-Streiber Method for detecting and identifying a variant c. difficile strain in a sample
US8889363B2 (en) 2009-07-27 2014-11-18 Biodics Method for the detection and identification of a variant C. difficile strain in a sample
WO2011063346A1 (en) * 2009-11-20 2011-05-26 Northshore University Health System Research Institute Targeting of the c-terminal segment of c. difficile toxin b for improved clinical diagnosis, prevention, and treatment
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
AU2011239470B2 (en) * 2010-04-15 2015-09-10 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease
RU2630663C9 (ru) * 2010-04-15 2017-11-29 Проджиникс Фармасьютикалс, Инк. Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний
LT2753352T (lt) 2010-09-03 2017-05-25 Valneva Austria Gmbh Išskirtas toksino a ir toksino b baltymų polipeptidas iš c. difficile ir jo panaudojimas
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
EP2632949B1 (en) * 2010-10-25 2017-09-13 National Research Council of Canada Clostridium difficile-specific antibodies and uses thereof
CA2834402A1 (en) * 2010-12-29 2012-07-05 Cangene Corporation Clostridium difficile antigens
US8906635B2 (en) 2011-02-28 2014-12-09 Northshore University Healthsystem Methods of diagnosing Clostridium difficile infection
NZ616035A (en) 2011-04-22 2016-03-31 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
AU2012321317B2 (en) * 2011-07-12 2016-01-28 Inovio Pharmaceuticals, Inc Novel clostridium difficile DNA vaccine
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
ES2729278T3 (es) * 2011-09-16 2019-10-31 Ucb Biopharma Sprl Anticuerpos neutralizantes de las exotoxinas principales tcda y tcdb de Clostridium difficile
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
JP6084631B2 (ja) 2011-12-08 2017-02-22 ノバルティス アーゲー Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン
DE102011121238A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
SG10201610123UA (en) * 2012-03-02 2017-01-27 Regeneron Pharma Human antibodies to clostridium difficile toxins
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
JPWO2014061783A1 (ja) * 2012-10-19 2016-09-05 株式会社イーベック クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
EP2925362A4 (en) * 2012-11-28 2016-07-20 Cnj Holdings Inc ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE
US10160797B2 (en) 2013-03-15 2018-12-25 Sanofi Pasteur Biologics, Llc Antibodies against Clostridium difficile toxins and methods of using the same
ES2940827T3 (es) * 2013-04-19 2023-05-11 Immuron Ltd Procedimientos y composiciones para el tratamiento y/o la profilaxis de la enfermedad asociada a Clostridium difficile
US9181632B1 (en) 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
WO2015100409A2 (en) * 2013-12-26 2015-07-02 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
BR112016018313A8 (pt) * 2014-02-10 2018-06-12 Igm Biosciences Inc Moléculas de ligação multiespecíficas iga
AU2015218909A1 (en) 2014-02-19 2016-08-04 Emergent Biosolutions Canada Inc. Marburg monoclonal antibodies
KR101966408B1 (ko) 2014-04-10 2019-04-05 오비아이 파머 인코퍼레이티드 항체，약학적 조성물 및 이의 용도
WO2015184454A1 (en) * 2014-05-30 2015-12-03 Case Western Reserve University Clostridium difficile culture medium
EP2957570B1 (en) 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
WO2016131157A1 (en) * 2015-02-19 2016-08-25 Immune Biosolutions Inc Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
WO2016156474A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a
WO2016156475A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
CN105039262B (zh) * 2015-07-10 2018-07-03 北京科兴中维生物技术有限公司 破伤风类毒素单克隆抗体及其应用
DK3307322T3 (da) 2015-09-04 2021-04-19 Primatope Therapeutics Inc Humaniserede anti-cd40-antistoffer og anvendelser deraf
SG11201804787UA (en) 2015-12-15 2018-07-30 Gilead Sciences Inc Human immunodeficiency virus neutralizing antibodies
WO2017189964A2 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018035407A1 (en) * 2016-08-19 2018-02-22 Enbiotix, Inc. Bacteriophages for neutralizing toxins and methods of use thereof
KR102324568B1 (ko) 2017-06-21 2021-11-10 길리애드 사이언시즈, 인코포레이티드 HIV gp120 및 CD3을 표적화하는 다중특이적 항체
JP7347849B2 (ja) * 2018-04-19 2023-09-20 ファースト ライト ダイアグノスティクス， インコーポレイテッド 標的の検出
WO2020231930A1 (en) * 2019-05-11 2020-11-19 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
WO2021219786A1 (en) * 2020-04-30 2021-11-04 Gottfried Himmler Anti-toxin secretory iga2 preparation
CN111499738B (zh) * 2020-06-03 2022-04-05 郑州师范学院 一种抗艰难梭菌肠毒素a的抗体
CN114853895B (zh) * 2020-11-30 2023-05-09 四川大学华西医院 一种抗糖基转移酶a亚单位的纳米抗体及其应用
CN117720651B (zh) * 2023-12-13 2024-05-31 北京新兴四寰生物技术有限公司 抗艰难梭菌毒素b的单克隆抗体及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) * 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5231003A (en) * 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
JPH08503121A (ja) * 1991-12-10 1996-04-09 デイナ・フアーバー・キヤンサー・インステイテユート 中和反応性ヒト抗−ｇｐ１２０組換え抗体、それをコードするｄｎａおよびその使用
US5466672A (en) 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
ATE366312T1 (de) 1994-10-24 2007-07-15 Ophidian Pharm Inc Impfstoff und antitoxine zur behandlung und vorbeugung von c. difficile krankheiten
GB9621295D0 (en) * 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
WO1998059053A1 (en) 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP2305303A3 (en) * 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
AU784012B2 (en) 1999-08-24 2006-01-12 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
ES2382891T3 (es) * 2000-05-26 2012-06-14 Immunex Corporation Uso de anticuerpos IL-4R y sus composiciones
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
TWI334439B (en) * 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
EP1519747A4 (en) * 2002-01-28 2006-03-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)
DK1916001T3 (da) * 2002-03-04 2011-07-18 Imclone Llc KDR-specifikke humane antistoffer og anvendelser deraf
CA2478386A1 (en) * 2002-03-21 2003-10-02 Eli Lilly And Company Antagonistic anti-hfas ligand human antibodies and fragments thereof
US7803913B2 (en) * 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
US7396913B2 (en) * 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
RU2377253C2 (ru) * 2002-12-02 2009-12-27 Амген Фремонт,Инк. Антитела, специфичные к фактору некроза опухолей, и их применение
US20040224408A1 (en) 2002-12-10 2004-11-11 Jean-Philippe Girard THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
US20070003561A1 (en) * 2003-07-08 2007-01-04 Sorensen Anders P Binding member towards pneumococcus surface adhesin a protein (psaa)
HUE025328T2 (en) * 2003-12-10 2016-03-29 Squibb & Sons Llc IP-10 antibodies and their use
CA2553946C (en) * 2004-02-06 2019-02-26 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
CA2553946A1 (en) 2005-08-06
US20160152694A1 (en) 2016-06-02
CY1111860T1 (el) 2015-11-04
NO20063767L (no) 2006-10-02
KR20120083534A (ko) 2012-07-25
US8609111B2 (en) 2013-12-17
US20100233181A1 (en) 2010-09-16
BRPI0507433B1 (pt) 2018-03-20
LT2857418T (lt) 2017-09-25
PL1766093T3 (pl) 2011-11-30
LTPA2017022I1 (lt) 2017-09-11
US9217029B2 (en) 2015-12-22
ES2533492T3 (es) 2015-04-10
HRP20110599T1 (hr) 2011-10-31
PL2857418T3 (pl) 2017-10-31
ES2366626T3 (es) 2011-10-24
BRPI0507433A (pt) 2007-07-03
LTC2270045I2 (lt) 2019-12-10
CY1119416T1 (el) 2018-03-07
US20210269511A1 (en) 2021-09-02
CY2017022I2 (el) 2017-11-14
US7625559B2 (en) 2009-12-01
EP2857418B1 (en) 2017-07-26
US20120288508A1 (en) 2012-11-15
ZA200606516B (en) 2011-01-26
EP2857418A1 (en) 2015-04-08
ES2643760T3 (es) 2017-11-24
JP5717300B2 (ja) 2015-05-13
HUE024962T2 (en) 2016-02-29
HUS1700028I1 (hu) 2017-07-28
PT2270045E (pt) 2015-04-08
CN101014620A (zh) 2007-08-08
DK2270045T3 (en) 2015-04-07
US8257709B2 (en) 2012-09-04
CA2553946C (en) 2019-02-26
CY2017022I1 (el) 2017-11-14
RS51908B (en) 2012-02-29
PT1766093E (pt) 2011-08-24
MXPA06008839A (es) 2008-03-07
JP5319622B2 (ja) 2013-10-16
JP2011019516A (ja) 2011-02-03
DK2857418T3 (en) 2017-10-23
WO2006121422A8 (en) 2007-04-26
HK1208873A1 (zh) 2016-03-18
EP2270045B8 (en) 2015-02-25
WO2006121422A3 (en) 2007-03-15
ATE512986T1 (de) 2011-07-15
US8236311B2 (en) 2012-08-07
EP2270045A1 (en) 2011-01-05
KR20070050863A (ko) 2007-05-16
AU2005320349B2 (en) 2010-04-08
JP2007533330A (ja) 2007-11-22
JP4588763B2 (ja) 2010-12-01
SI1766093T1 (sl) 2011-12-30
AU2005320349A1 (en) 2006-08-24
BRPI0507433B8 (pt) 2018-04-10
NO2017032I1 (no) 2017-07-07
EP2270045B1 (en) 2014-12-31
NZ580828A (en) 2011-09-30
AU2005320349B8 (en) 2010-04-22
KR101332927B1 (ko) 2013-11-26
LUC00025I2 (zh) 2017-09-08
EP1766093B1 (en) 2011-06-15
US20050287150A1 (en) 2005-12-29
AU2005320349C1 (en) 2019-06-13
BRPI0507433C1 (pt) 2021-05-25
NZ548821A (en) 2009-12-24
EP1766093A2 (en) 2007-03-28
AU2005320349A8 (en) 2008-08-07
DK1766093T3 (da) 2011-10-03
CN101014620B (zh) 2012-05-09
KR20120003017A (ko) 2012-01-09
PL2270045T3 (pl) 2015-06-30
JP2013153750A (ja) 2013-08-15
PT2857418T (pt) 2017-10-20
SI2857418T1 (en) 2018-01-31
WO2006121422A2 (en) 2006-11-16
SI2270045T1 (sl) 2015-06-30
LUC00025I1 (zh) 2017-07-06
HK1102287A1 (en) 2007-11-09
US20140120614A1 (en) 2014-05-01
US20100233182A1 (en) 2010-09-16
KR101332994B1 (ko) 2013-11-26
HUE034552T2 (en) 2018-02-28
US20180208643A1 (en) 2018-07-26
NO340300B1 (no) 2017-03-27

Similar Documents

Publication Publication Date Title
HUS1700028I1 (hu) Antitestek a Clostridium difficile toxinok ellen és azok felhasználásai
WO2006118772A3 (en) Fcrn antibodies and uses thereof
WO2006119062A3 (en) Sclerostin epitopes
TW200716667A (en) Binding agents
MX2007004247A (es) Agentes de aglutinacion especifica a angiopoyetina-2.
WO2006053301A3 (en) Fc variants with altered binding to fcrn
TWI370136B (en) Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses
WO2005092925A3 (en) Immunoglobulin variants outside the fc region
SG170793A1 (en) Anti-mn antibodies and methods of using same
WO2006085938A3 (en) Il-13 binding agents
WO2007116360A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.
MX2010001237A (es) Nuevos anticuerpos.
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
WO2006116319A3 (en) Reagents that bind ccx-ckr2
WO2007002525A3 (en) Tomoregulin antibodies and uses thereof
CY1116371T1 (el) Αντισωματα εναντι των τοξινων toy clostridium difficile (κλωστηριδιο το δυσκολο) και χρησεις εξ αυτων
WO2006136892A3 (de) Neuartige cherlasky - fusionsproteine enthalten antikorperbindeproteine oder ihre regionen